Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/4/2025 | $10.00 | Buy | D. Boral Capital |
4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)
4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)
424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)
10-Q - Tevogen Bio Holdings Inc. (0001860871) (Filer)
424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)
D. Boral Capital initiated coverage of Tevogen Bio with a rating of Buy and set a new price target of $10.00
WARREN, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced that Founder and CEO of Tevogen, Dr. Ryan Saadi, donated 10,000 of his personal shares of common stock to the Opportunity Project, a Millburn, N.J.–based nonprofit dedicated to empowering individuals with brain injuries through its innovative Clubhouse model. Founded in 1993, Opportunity Project has served more than 600 individuals and their families, providing programs that foster independence, self‑esteem, and community reintegration. "This donation is a small way to express my admiration for Opportunity Project's work and its impact on so many lives," said D
WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or the "Company") (NASDAQ:TVGN), today issued the following statement from Ryan Saadi, M.D., M.P.H., Founder and CEO. "Tevogen is an asset-rich enterprise, and we plan on sharing a comprehensive inventory of Tevogen's wholly owned internally developed assets and their standard methodology valuation. These intangible assets are not reflected in financial reports due to US GAAP accounting rules, but they do underscore the magnitude of what we have built in such a short time. It is important for shareholders to understand that these assets, including our intellectual property portfolio, drug development
Tevogen.AI to explore external market opportunities as a potential revenue source. Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and potentially accelerating cancer immunotherapy development.Tevogen.AI to develop enhanced analytics and visualization tools, for the PredicTcell model to support its internal R&D teams. WARREN, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that its artificial intelligence initiative, Tevogen.AI, is expanding its collaboration with Microsoft (NASDAQ:MSFT) and Databricks, to build the beta version of its foundational PredicTce
4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)
4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)
4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)
WARREN, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today reminds that CEO Dr. Ryan Saadi MD, MPH will participate in BioNJ's Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald. The conference, held on May 13, 2025,
WARREN, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announces CEO Dr. Ryan Saadi, MD, MPH, will participate in BioNJ's Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald. The conference, held on May 13, 2025,
WARREN, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, is pleased to share that Founder and CEO, Ryan Saadi, MD, MPH, has been named to the 2025 Health Care Power List by NJBIZ. This recognition highlights Dr. Saadi's leadership and commitment to advancing healthcare innovation and accessibility in New Jersey and beyond. This announcement coincides with a significant milestone in Tevogen's growth, the appointment of David E. Banko, as Global Head of Government Affairs and Patient Access. Mr. Banko's focus will include a
WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company, shares a summary of the Company's 2024 financing activity at the one year anniversary of being listed on the Nasdaq exchange. On October 29, Tevogen Bio signed a letter of intent with CD8 Technology Services to build an up to $50 million turn-key research and development facility for Tevogen Bio's use. This arrangement, when finalized, will not dilute existing Tevogen Bio shareholders.On August 15, Tevogen Bio entered into a definitive agreement for a $6 million Series C Preferred Stock investment ("Series C"). The
WARREN, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has entered into a definitive agreement for a $6.0 million Series C Preferred Stock investment with The Patel Family, LLP. The shares of Series C Preferred Stock will have a 7.5% dividend per year, accruing and payable quarterly. The Series C Preferred Stock is convertible into shares of common stock after 6 months at the election of the holder, and callable by Tevogen for redemption after 5 years at Tevogen's e
WARREN, N.J., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has announced financial results for the fiscal quarter ending June 30, 2024, and filed its quarterly report on Form 10-Q with the Securities and Exchange Commission. Tevogen's reported $5.1 million net cash used in operating activities and $33.0 million in non-cash expenses for the six months ending June 30, 2024. The key non-cash expense items included $30.5 million in stock-based compensation expenses. The Com
SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)
SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)
SC 13G - Tevogen Bio Holdings Inc. (0001860871) (Subject)